Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure

Benjamin French, Le Wang, Bonnie Ky, Jeffrey Brandimarto, Anupam Basuray, James C. Fang, Nancy K Sweitzer, Thomas P. Cappola

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Clinical studies have suggested the prognostic value of galectin-3, a marker of fibrosis, in chronic heart failure. However, the specific role of galectin-3, compared with established biomarkers, remains uncertain. Methods and Results: The Penn Heart Failure Study was an ambulatory heart failure cohort that included 1385 participants with reduced (1141), preserved (106), and recovered (138) left ventricular ejection fraction (LVEF). Cox regression models determined the association between galectin-3 and risk of all-cause mortality, cardiac transplantation, or placement of a ventricular assist device. Receiver operating characteristic curves compared the prognostic accuracy of galectin-3, high-sensitivity soluble Toll-like receptor 2 (ST2), troponin I, and B-type natriuretic peptide (BNP) at 1 and 5 years. Higher galectin-3 levels were associated with an increased risk of adverse events (adjusted hazard ratio of 1.96 for each doubling in galectin-3; P <.001). This association was most pronounced among participants with preserved LVEF (adjusted hazard ratio 3.30; P <.001). At 5 years, galectin-3 was the most accurate discriminator of risk among participants with preserved LVEF (area under the curve 0.782; P = .81 vs high-sensitivity ST2; P = .029 vs troponin I; P = .35 vs BNP). BNP was most accurate among participants with reduced and recovered LVEF (areas under the curves 0.716 and 0.728, respectively). Conclusions: Galectin-3 could have prognostic value for long-term events among patients with heart failure and preserved ejection fraction.

Original languageEnglish (US)
JournalJournal of Cardiac Failure
DOIs
StateAccepted/In press - May 21 2015

Fingerprint

Galectin 3
Heart Failure
Stroke Volume
Brain Natriuretic Peptide
Toll-Like Receptor 2
Troponin I
Area Under Curve
Heart-Assist Devices
Heart Transplantation
Proportional Hazards Models
ROC Curve
Fibrosis
Biomarkers
Mortality

Keywords

  • Biomarker
  • Ejection fraction
  • Risk stratification
  • Ventricular function

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

French, B., Wang, L., Ky, B., Brandimarto, J., Basuray, A., Fang, J. C., ... Cappola, T. P. (Accepted/In press). Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2015.10.022

Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure. / French, Benjamin; Wang, Le; Ky, Bonnie; Brandimarto, Jeffrey; Basuray, Anupam; Fang, James C.; Sweitzer, Nancy K; Cappola, Thomas P.

In: Journal of Cardiac Failure, 21.05.2015.

Research output: Contribution to journalArticle

French, Benjamin ; Wang, Le ; Ky, Bonnie ; Brandimarto, Jeffrey ; Basuray, Anupam ; Fang, James C. ; Sweitzer, Nancy K ; Cappola, Thomas P. / Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure. In: Journal of Cardiac Failure. 2015.
@article{5b5d27b912a745199231229b451e3122,
title = "Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure",
abstract = "Background: Clinical studies have suggested the prognostic value of galectin-3, a marker of fibrosis, in chronic heart failure. However, the specific role of galectin-3, compared with established biomarkers, remains uncertain. Methods and Results: The Penn Heart Failure Study was an ambulatory heart failure cohort that included 1385 participants with reduced (1141), preserved (106), and recovered (138) left ventricular ejection fraction (LVEF). Cox regression models determined the association between galectin-3 and risk of all-cause mortality, cardiac transplantation, or placement of a ventricular assist device. Receiver operating characteristic curves compared the prognostic accuracy of galectin-3, high-sensitivity soluble Toll-like receptor 2 (ST2), troponin I, and B-type natriuretic peptide (BNP) at 1 and 5 years. Higher galectin-3 levels were associated with an increased risk of adverse events (adjusted hazard ratio of 1.96 for each doubling in galectin-3; P <.001). This association was most pronounced among participants with preserved LVEF (adjusted hazard ratio 3.30; P <.001). At 5 years, galectin-3 was the most accurate discriminator of risk among participants with preserved LVEF (area under the curve 0.782; P = .81 vs high-sensitivity ST2; P = .029 vs troponin I; P = .35 vs BNP). BNP was most accurate among participants with reduced and recovered LVEF (areas under the curves 0.716 and 0.728, respectively). Conclusions: Galectin-3 could have prognostic value for long-term events among patients with heart failure and preserved ejection fraction.",
keywords = "Biomarker, Ejection fraction, Risk stratification, Ventricular function",
author = "Benjamin French and Le Wang and Bonnie Ky and Jeffrey Brandimarto and Anupam Basuray and Fang, {James C.} and Sweitzer, {Nancy K} and Cappola, {Thomas P.}",
year = "2015",
month = "5",
day = "21",
doi = "10.1016/j.cardfail.2015.10.022",
language = "English (US)",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure

AU - French, Benjamin

AU - Wang, Le

AU - Ky, Bonnie

AU - Brandimarto, Jeffrey

AU - Basuray, Anupam

AU - Fang, James C.

AU - Sweitzer, Nancy K

AU - Cappola, Thomas P.

PY - 2015/5/21

Y1 - 2015/5/21

N2 - Background: Clinical studies have suggested the prognostic value of galectin-3, a marker of fibrosis, in chronic heart failure. However, the specific role of galectin-3, compared with established biomarkers, remains uncertain. Methods and Results: The Penn Heart Failure Study was an ambulatory heart failure cohort that included 1385 participants with reduced (1141), preserved (106), and recovered (138) left ventricular ejection fraction (LVEF). Cox regression models determined the association between galectin-3 and risk of all-cause mortality, cardiac transplantation, or placement of a ventricular assist device. Receiver operating characteristic curves compared the prognostic accuracy of galectin-3, high-sensitivity soluble Toll-like receptor 2 (ST2), troponin I, and B-type natriuretic peptide (BNP) at 1 and 5 years. Higher galectin-3 levels were associated with an increased risk of adverse events (adjusted hazard ratio of 1.96 for each doubling in galectin-3; P <.001). This association was most pronounced among participants with preserved LVEF (adjusted hazard ratio 3.30; P <.001). At 5 years, galectin-3 was the most accurate discriminator of risk among participants with preserved LVEF (area under the curve 0.782; P = .81 vs high-sensitivity ST2; P = .029 vs troponin I; P = .35 vs BNP). BNP was most accurate among participants with reduced and recovered LVEF (areas under the curves 0.716 and 0.728, respectively). Conclusions: Galectin-3 could have prognostic value for long-term events among patients with heart failure and preserved ejection fraction.

AB - Background: Clinical studies have suggested the prognostic value of galectin-3, a marker of fibrosis, in chronic heart failure. However, the specific role of galectin-3, compared with established biomarkers, remains uncertain. Methods and Results: The Penn Heart Failure Study was an ambulatory heart failure cohort that included 1385 participants with reduced (1141), preserved (106), and recovered (138) left ventricular ejection fraction (LVEF). Cox regression models determined the association between galectin-3 and risk of all-cause mortality, cardiac transplantation, or placement of a ventricular assist device. Receiver operating characteristic curves compared the prognostic accuracy of galectin-3, high-sensitivity soluble Toll-like receptor 2 (ST2), troponin I, and B-type natriuretic peptide (BNP) at 1 and 5 years. Higher galectin-3 levels were associated with an increased risk of adverse events (adjusted hazard ratio of 1.96 for each doubling in galectin-3; P <.001). This association was most pronounced among participants with preserved LVEF (adjusted hazard ratio 3.30; P <.001). At 5 years, galectin-3 was the most accurate discriminator of risk among participants with preserved LVEF (area under the curve 0.782; P = .81 vs high-sensitivity ST2; P = .029 vs troponin I; P = .35 vs BNP). BNP was most accurate among participants with reduced and recovered LVEF (areas under the curves 0.716 and 0.728, respectively). Conclusions: Galectin-3 could have prognostic value for long-term events among patients with heart failure and preserved ejection fraction.

KW - Biomarker

KW - Ejection fraction

KW - Risk stratification

KW - Ventricular function

UR - http://www.scopus.com/inward/record.url?scp=84951923195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951923195&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2015.10.022

DO - 10.1016/j.cardfail.2015.10.022

M3 - Article

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

ER -